Unichem Laboratories Limited has issued notice for its 63rd Annual General Meeting to be held on Tuesday, 11th August 2026 at 3:30 p.m. IST through Video Conference/Other Audio-Visual Means without physical attendance.

Ordinary Business

1. To receive, consider and adopt the Audited Standalone Financial Statements for the financial year ended 31st March 2026 with Reports of Board of Directors and Auditors

2. To receive, consider and adopt the Audited Consolidated Financial Statements for the financial year ended 31st March 2026 with Report of Auditors

3. To appoint a Director in place of Mr. Pabitrakumar Bhattacharyya (DIN: 07131152) who retires by rotation and is eligible for re-appointment

Special Business

4. Special Resolution: Re-appointment and remuneration terms of Mr. Pabitrakumar Bhattacharyya as Managing Director and Chief Executive Officer for a further period of three years with effect from 10th August 2026 to 9th August 2029

Key Terms of MD & CEO Re-appointment:

  • Basic Salary: ₹20,00,000 per month effective 10th August 2026, with increments subject to ceiling of ₹28,00,000 per month
  • Commission: Up to 1% of net profits computed under Section 198 of Companies Act, 2013
  • Provident Fund contributions as per company scheme
  • National Pension Scheme contributions as per rules
  • Gratuity: Half month's salary for each completed year of service
  • Perquisites: House Rent allowance @30% of salary, medical/hospitalization expenses, Leave Travel Concession (once yearly, ceiling of one month salary), company car with driver, communication facilities, personal accident insurance
  • Minimum remuneration payable in case of loss/inadequacy of profits as per Schedule V provisions

5. Ordinary Resolution: Ratification of remuneration payable to Kishore Bhatia & Associates, Cost Accountants (Firm Registration No. 00294) for auditing cost records for financial year ending 31st March 2027

  • Remuneration: ₹6,00,000 (Rupees Six lakhs only) plus applicable taxes and reimbursement of out-of-pocket expenses

Voting Arrangements

  • Remote e-Voting period: Friday, 7th August 2026 (9:00 a.m.) to Monday, 10th August 2026 (5:00 p.m.)
  • Record date: Tuesday, 4th August 2026
  • e-Voting conducted through NSDL platform
  • Physical attendance dispensed with due to virtual meeting
  • Scrutinizer: Mr. Alwyn D'Souza (or Mr. Jay D'Souza) of M/s. Alwyn Jay & Co., Practicing Company Secretaries

Financial Performance Context (As per Explanatory Statement)

The explanatory statement provides financial context for the MD's reappointment:

Table 1 - Financial Performance (₹ in crores):

| Period | Total Income (Standalone) | Total Income (Consolidated) | Profit after tax (Standalone) | Profit after tax (Consolidated) |

| 2023-24 | 1,472.55 | 1,816.70 | (92.18) | (93.76) |

| 2024-25 | 1,776.53 | 2,146.29 | 162.96 | 137.52 |

| 2025-26 | 1,475.19 | 2,264.91 | 158.94 | 252.84 |

Table 2 - Foreign Exchange Earnings (Standalone, ₹ in crores):

| 2023-24: ₹1,287.67 | 2024-25: ₹1,484.01 | 2025-26: ₹1,562.05 |

Table 3 - Foreign Investments (as of 31st March 2026):

  • Niche Generics Limited, UK (WOS): ₹69.09 crores (impairment provided)
  • Unichem Farmaceutica Do Brasil Ltda, Brazil (WOS): ₹70.87 crores (impairment provided)
  • Unichem Pharmaceuticals (USA) INC (WOS): ₹38.25 crores
  • Unichem SA (Pty) Limited, South Africa (WOS): ₹0.12 crores
  • Unichem (China) Pvt. Ltd. (WOS): ₹7.21 crores
  • Synchron Research Services Pvt Ltd (Associate): ₹5.69 crores (impairment provided)

Additional Information

  • The company is an integrated pharmaceutical company with manufacturing facilities in Goa, Baddi (Himachal Pradesh), Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh), Roha and Kolhapur (Maharashtra)
  • R&D Centre called Centre of Excellence located in Goa
  • Significant revenue from regulated markets including US, Brazil and Europe
  • The notice references acquisition by Ipca Laboratories Limited in 2023 and subsequent turnaround strategy
  • RTA: MUFG Intime India Private Limited, Mumbai